, a developer of innovative medications for serious central nervous system diseases, announced today that it provides executed an agreement with TG United, Inc. Of Brooksville, Florida, to provide commercial-scale manufacturing capabilities for reaZin. Adeona is developing reaZin, its product applicant for the dietary management of Alzheimer’s disease and mild cognitive impairment, as a prescription medical food. Top-line outcomes from Adeona’s clinical research analyzing reaZin for the dietary administration of Alzheimer’s disease and mild cognitive impairment were provided the other day at the 63rd Annual Meeting of the American Academy of Neurology.‘This well executed study clearly implies that treating the sickest coronary attack individuals early and aggressively provides a survival benefit that’s sustained years after treatment,’ says Elizabeth G. Nabel, M.D., Director of the National Center, Lung, and Bloodstream Institute. ‘These results should guide doctors to consider crisis revascularization for patents with cardiogenic shock complicating coronary attack,’ says Dr. Nabel. ‘Our study shows a significant survival benefit that’s sustained up to 11 years. This benefit extends also to selected patients over the age of 75,’ says Dr. Hochman, Clinical Chief of the Leon H. Charney Division of Director and Cardiology of Cardiovascular Clinical Analysis at New York University School of Medication.